Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.

Abstract

BACKGROUND:

Despite current recommendations, many patients with persistent asthma are still treated with bronchodilators alone.

OBJECTIVE:

The safety and efficacy of two once daily dosing regimens (200 microg and 400 microg) of mometasone furoate (MF) administered in the morning by using a dry-powder inhaler (DPI) were compared with those of a twice daily dosing regimen (200 microg administered twice daily) in patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists.

METHODS:

All patients (306 patients; age range, 12-70 years) were given a diagnosis of asthma for at least 6 months before enrollment in this 12-week, placebo-controlled, double-blind, randomized study. The primary efficacy variable was change in FEV(1) from baseline to endpoint (last evaluable visit).

RESULTS:

At endpoint, FEV(1) was significantly improved (P < or =.02) after MF-DPI 400 microg once daily morning treatment and MF-DPI 200 microg twice daily treatment (16.0% and 16.1%, respectively) compared with placebo (5.5%). The improvement seen with MF-DPI 200 microg once daily morning treatment (10.4%) was not significantly different from that with placebo. Secondary efficacy variables also showed significant improvement for the MF-DPI 400 microg once daily morning treatment group and the MF-DPI 200 microg twice daily treatment group compared with the placebo group. All doses of MF administered by means of a DPI were well tolerated.

CONCLUSION:

This is the first study to demonstrate that a total daily dose of 400 microg of MF administered by means of a DPI is an effective treatment for patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists. This treatment was equally effective when administered either as a once daily or twice daily regimen.

• Authors: J P Kemp, R B Berkowitz, S D Miller, J J Murray, K Nolop, J E Harrison
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 106 Issue 3 Pg. 485-92 (Sep 2000) ISSN: 0091-6749 [Print] United States
• PMID: 10984368 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents
• Pregnadienediols
• Mometasone Furoate
• Albuterol

Topics

• Adolescent
• Adult
• Aged
• Albuterol (administration & dosage, adverse effects)
• Anti-Inflammatory Agents (administration & dosage, adverse effects)
• Asthma (drug therapy)
• Circadian Rhythm
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Mometasone Furoate
• Pregnadienediols (administration & dosage, adverse effects)
• Respiratory Function Tests